Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination.
The immaturity of the immune system increases the susceptibility of young infants to infectious diseases and prevents the induction of protective immune responses by vaccines. We previously reported that Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination induces a potent Th1 response to mycobacterial Ags in newborns. In this study, we evaluated the influence of BCG on the response to unrelated vaccines given in early life. Newborns were randomly allocated to one of three study groups receiving BCG at birth, when infants received their first dose of hepatitis B and oral polio vaccines; at 2 mo of age, when infants received their first dose of diphtheria and tetanus vaccines; or at 4.5 mo of age, when immune responses to vaccines were measured. Administration of BCG at the time of priming markedly increased the cellular and Ab responses to the hepatitis B vaccine, but had only a limited influence on the cytokine response to tetanus toxoid and no effect on the Ab responses to tetanus and diphtheria toxoids. Although BCG induced a potent Th1-type response to mycobacterial Ags, it promoted the production of both Th1- and Th2-type cytokines in response to unrelated vaccines. The effect of BCG was apparent at the systemic level, as it increased the Ab response to oral polio vaccine. These results demonstrate that BCG influences the immune response to unrelated Ags in early life, likely through its influence on the maturation of dendritic cells.
Ota
Martin O C
MO
Medical Research Council Laboratories, Banjul, The Gambia.
Vekemans
Johan
J
Schlegel-Haueter
Susanna E
SE
Fielding
Katherine
K
Sanneh
Mariama
M
Kidd
Michael
M
Newport
Melanie J
MJ
Aaby
Peter
P
Whittle
Hilton
H
Lambert
Paul-Henri
PH
McAdam
Keith P W J
KP
Siegrist
Claire-Anne
CA
Marchant
Arnaud
A
D000367:Age Factors; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D000914:Antibodies, Viral / Q000096:biosynthesis*; D001500:BCG Vaccine / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis*; D004168:Diphtheria Toxoid / Q000276:immunology; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D007231:Infant, Newborn / Q000276:immunology*; D011055:Poliovirus Vaccine, Oral / Q000276:immunology; D011446:Prospective Studies; D013745:Tetanus Toxoid / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism
D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D001500:BCG Vaccine; D016207:Cytokines; D004168:Diphtheria Toxoid; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D017325:Hepatitis B Vaccines; D011055:Poliovirus Vaccine, Oral; D013745:Tetanus Toxoid